Mylan's deal to acquire Strides Arcolab's unit looks set to proceed

22 August 2013

US generics and specialty drugmaker Mylan (NYSE: MYL) $1.6-billion foreign direct investment proposal - aiming to acquire Indian pharma firm Strides Arcolab's (BO: 532532) Agila Specialties unit (The Pharma Letter February 28) - has finally seen the green light, reports the Hindustan Times. India’s Prime Minister Manmohan Singh last Friday cleared the Strides Arcolab-Mylan deal, overruling the concerns raised by Department of Industrial Policy and Promotion (DIPP) and Ministry of Health (TPL July 9).

The Foreign Investment Promotion Board (FIPB) had kept its approval on the deal in abeyance till there was clarity on “brownfield” foreign direct investment (FDI) norms - one in which acquisition is built into a new project. Now, the deal will be brought to the Cabinet Committee on Economic Affairs (CCEA) under existing policy to get the final approval, the newspaper noted.

Conditions imposed

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK